Substrate-Induced Motion between TM4 and TM7 of the Glutamate Transporter EAAT1 Revealed by Paired Cysteine Mutagenesis

Wenlong Zhang, Xiuping Zhang, and Shaogang Qu

Central Laboratory, Shunde Hospital, Southern Medical University (The First People’s Hospital of Shunde Foshan), Foshan, Guangdong, China (W.Z., S.Q.); and Key Laboratory of Mental Health of the Ministry of Education (W.Z., S.Q.) and Teaching Center of Experimental Medicine, School of Basic Medical Sciences (X.Z.), Southern Medical University, Guangzhou, Guangdong, China

Received May 27, 2018; accepted October 16, 2018

ABSTRACT

To maintain efficient synaptic communication, glutamate transporters reuptake glutamate from the synaptic cleft and prevent glutamate concentrations from reaching neurotoxic levels. The number of amino acid residues of the transmembrane (TM) domain 4b-4c loop of mammalian excitatory amino acid transporters (EAATs) is 50 amino acids more than that of the prokaryotic homolog. To investigate the spatial proximity and functional significance of residues in glutamate transporters, cysteine pairs were introduced at positions A243 of the TM4b-4c loop and T396 or A414 of TM7, respectively. The transport activity of double mutants A243C/T396C and A243C/A414C was inhibited by Cu(II) (1,10-phenanthroline)3 [copper phenanthroline (CuPh)] and cadmium ions, but the uptake activity of corresponding single mutants remained unchanged. Treatment with dithiothreitol after CuPh restored much of the transport activity. The inhibitory effects of CuPh and cadmium could only be detected when cysteine pairs are in the same polypeptide. Therefore, we suggest that the formation of these disulfide bonds occurs intramolecularly. Glutamate, potassium, and DL-threo-β-benzoyloxyaspartate facilitated crosslinking in the A243C/T396C transporter and this suggests that the TM4b-4c loop and β-bridge region in TM7 were drawn into close proximity to each other in the inward- and outward-facing conformation of EAAT1. Thus, these data provide evidence that substrate-induced structural rearrangements occur between the TM4b-4c loop and TM7 during the transport cycle.

Introduction

Glutamate is the primary excitatory neurotransmitter in the mammalian central nervous system. It is continually pumped into the cytoplasm to prevent hyperexcitability and neurotoxicity by excitatory amino acid transporters (EAATs) located in the plasma membranes of glial cells and neurons (Amara and Fontana, 2002; Kanai and Hediger, 2004). Five members of the glutamate transporter (EAAT1–EAAT5 transporters), expressed at the plasma membrane of glial cells and neurons, have been cloned (Kanai and Hediger, 1992; Pines et al., 1992; Storck et al., 1992; Arriza et al., 1994, 1997; Fairman et al., 1995). They showed an overall amino acid identity of ~50% (Arriza et al., 1997). EAAT1 and EAAT2 are responsible for most of the glutamate uptake in the rodent brain (Lehre and Danbolt, 1998). Glutamate uptake is an electrogenic process facilitated by Na+-K+-ATPase (Kanner and Sharon, 1978; Brew and Attwell, 1987; Wadiche et al., 1995), where the transport cycle causes the binding of the substrate together with three sodium ions and one proton. Upon binding, these are released into the cytoplasm, and the transporter for the next cycle is reset following the counter transport of a single potassium ion (Pines et al., 1995; Zerangue and Kavanaugh, 1996; Levy et al., 1998). Crystal structures from Pyrococcus horikoshii [the glutamate transporter homolog from P. horikoshii (GltPh)] have advanced our insight into the glutamate transporter (Yernool et al., 2004; Boudker et al., 2007; Reyes et al., 2009; Verdun and Boudker, 2012). GltPh is a trimer where each monomer is a functional unit (Yernool et al., 2004). The protomer contains eight transmembrane (TM) domains (TM1–TM8) and two oppositely oriented hairpin loops (HPs), one between domains 6 and 7 (HP1) and the other between domains 7 and 8 (HP2). HP2 has been suggested to act as the extracellular gate to bind the substrate, while HP1 has been demonstrated to act as the intracellular gate (Yernool et al., 2004; Boudker et al., 2007; Zerangue and Kavanaugh, 1996).

ABBREVIATIONS: ChCl, choline chloride; CL-EAAT1, cysteine-less excitatory amino acid transporter 1; CuPh, copper phenanthroline; DL-TBOA, DL-threo-β-benzoyloxyaspartate; DTT, DL-dithiothreitol; EAAT, excitatory amino acid transporter; FRET, fluorescence resonance energy transfer; GltPh, glutamate transporter homolog from Pyrococcus horikoshii; HP, hairpin loop; MTSEA, 2-aminoethyl methanethiosulfonate; MTSET, [2-(trimethylammonium)ethyl] methanethiosulfonate; TM, transmembrane.
Qu and Kanner, 2008; Shrivastava et al., 2008; Crisman et al., 2009; Teichman et al., 2009; Canul-Tec et al., 2017). This is a common phenomenon for the eukaryotic glutamate transporters, and thus it serves as a model that can be used to probe conformational changes driving transport in the EAATs (Grewer et al., 2005; Koch and Larsson, 2005; Koch et al., 2007a; Leary et al., 2007). In addition, the unusual topology of GltPh is highly consistent with that of eukaryotic transporters, which has been studied in biochemistry (Boudker et al., 2007; Crisman et al., 2009; Teichman et al., 2009). However, GltPh only shares ~35% sequence identity with the EAATs (Slotboom et al., 1999; Yernool et al., 2004). The amino acid insertions or deletions may make this homolog a limited structural model to uncover the molecular mechanism of the EAAT proteins. There are more 53 amino acid residues in the TM4b-4c loop of EAAT1 than in GltPh (Yernool et al., 2004) (Fig. 1A). Additionally, it had been declared that the transport domain, which included TM3, TM6–TM8, and reentrant helical loops (HP1 and HP2), moved relatively to the scaffold domain, including transmembrane helices TM1–TM2 and TM4–TM5 (Groeneveld and Slotboom, 2007; Crisman et al., 2009; Reyes et al., 2009).

To investigate the spatial location change between the TM4b-4c loop and TM7 during the transport cycle, we performed an oxidative crosslinking study (Fig. 1, A–C). We designed double cysteine transporters (by introducing pairs of cysteine residues on the cysteine-less version of EAAT1) and substitutions for the three endogenous cysteine residues, C186S, C252A, and C375G, leading to about 75% transport activity of the wild-type EAAT1 (Seal and Amara, 1998). Designing double cysteine transporters (by introducing pairs of cysteine residues on the cysteine-less version of EAAT1) and substitutions for the three endogenous cysteine residues, C186S, C252A, and C375G, leading to about 75% transport activity of the wild-type EAAT1 (Seal and Amara, 1998).

Materials and Methods

Generation and Subcloning of Mutants. The cysteine-less EAAT1 [(CL-EAAT1), Rattus norvegicus, GenBank: X63744.1] is constructed in the vector pBluescript SK(−) (Stratagene, La Jolla, CA). CL-EAAT1 serves as a template for site-directed mutagenesis. The QuikChange Site-Directed Mutagenesis Kit (TOYOBO, Osaka, Japan) and polymerase chain reaction were used to generate mutant transporters. All mutant transporters were ascertained by full-length sequencing (Sangon Biotech, Shanghai, China).

Cell Culture and Transient Transfections. HeLa cells were purchased from ATCC (Manassas, VA) and grown on a 24-well plate using Dulbecco’s modified Eagle’s medium (Thermo Fischer Scientific, Waltham, MA) containing 10% fetal calf serum (ExCell Biology, Shanghai, China), 200 U/ml penicillin, and 200 μg/ml streptomycin (Beyotime Biotechnology, Shanghai, China). After 20 hours, HeLa cells were transiently infected with recombinant vaccinia/T7 virus (Fuerst et al., 1986). The CL-EAAT1 or mutant constructs were transfected into HeLa cells with Lipo6000 Transfection Reagent (Beyotime Biotechnology) and cultured at 37°C, 5% CO2, for 20 hours.

Transport Assay. HeLa cells expressing the mutant were washed once with 1 ml choline chloride (ChCl) solution (150 mM ChCl, 5 mM KPi, pH 7.4, 0.5 mM MgSO4, and 0.3 mM CaCl2) after transfection for 20 hours. Then, the NaCl solution [150 mM NaCl, 5 mM KPi, pH 7.4, 0.5 mM MgSO4, and 0.3 mM CaCl2] containing 0.4 μCi (0.15 μM) D-[3H]-aspartate (PerkinElmer, Waltham, MA) was added to incubate for 10 minutes. Ice-cold NaCl solution was added to terminate the reaction, followed by washing twice with NaCl solution. Then, 1% SDS was added to lyse cells and radioactivity was detected. All data were calculated after subtracting the value of the transfection of vector pBluescript SK(−).

Cell Surface Biotinylation. Cell surface expression levels of mutants were examined using the membrane-impermeable biotinylation reagent EZ-Link Sulfo-NHS-SS-biotin (Thermo Fisher Scientific).
HeLa cells transfected with CL-EAAT1 or mutants were washed twice with ice-cold phosphate-buffered saline (PH 8.0), and then incubated with EZ-Link Sulfo-NHS-SS-biotin (0.5 mg/ml in phosphate-buffered saline) for 20 minutes. Cells were washed twice with 100 mM glycine to terminate the reaction. Then, the cells were lysed on ice with cell lysis buffer (20 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100, sodium pyrophosphate, β-glycerophosphate, EDTA, Na3VO4, leupeptin, and 1 mM phenylmethylsulfonyl fluoride) for 20 minutes, and the supernatants (i.e., the total proteins) were collected after centrifugation (12,000 rpm for 20 minutes at 4°C). The cell debris was discarded. Pierce Streptavidin Agarose (Thermo Fisher Scientific) was added to bind the biotin-labeled cell membrane proteins for 1 hour at 4°C. Streptavidin-agarose beads were centrifuged 12,000 rpm for 1 minute at 4°C. Supernatants (the nonbiotinylated proteins) were removed to new tubes. Streptavidin-agarose beads were washed three times through 1 ml ice-cold lysis buffer to remove the nonbiotinylated proteins. Centrifugation was performed at 12,000 rpm for 1 minute at 4°C. The membrane protein samples (the biotinylated proteins), total proteins, and nonbiotinylated proteins were used for western blot (Rong et al., 2016).

**Western Blot Analysis.** Samples were mixed with protein loading buffer and boiled at 55°C for 30 minutes. Protein samples were fractionated by 10% SDS-PAGE, transferred onto polyvinylidene difluoride membranes, and blocked with 5% bovine serum albumin for 1.5 hours at room temperature. The membranes were incubated with anti-EAAT1 antibody (Santa Cruz, Dallas, TX) for 16 hours at 4°C. Integrin (Santa Cruz), αβ-tubulin (Santa Cruz), and β-actin (Beyotime Biotechnology) were used as internal controls. Then, the blots were incubated with secondary antibodies for 1 hour at room temperature. Secondary antibodies were horseradish peroxidase–labeled donkey anti-goat IgG (H+L) for EAAT1 and integrin, horse-radish peroxidase–labeled goat anti-mouse IgG (H+L) for αβ-tubulin, and horseradish peroxidase–labeled goat anti-rabbit IgG (H+L) for αβ-tubulin. All secondary antibodies were purchased from Beyotime Biotechnology. The blots were detected by chemiluminescent BeyoECL Plus (Beyotime Biotechnology). Membrane polymer protein expression, the nonbiotinylated proteins, and the total proteins were calculated by the optical density of bands for CL-EAAT1 and its mutants divided by the corresponding value for integrin, αβ-tubulin, and β-actin expression in individual samples. Membrane expression, the nonbiotinylated proteins, and the total proteins of CL-EAAT1 were designated as 100%. The uptake activity of mutant was normalized to the expression of membrane protein as the relative intrinsic activity, which was calculated as follows: the uptake activity of mutant/the expression of membrane protein polymer in mutant.

**Inhibition of Transport by CuPh.** After HeLa cells were transfected with CL-EAAT1 and mutant for 18–20 hours in 24-well plates, ChCl solution was added to wash the cells twice, and then the cells were incubated with different concentrations of CuPh at room temperature for 5 minutes, followed by washing twice with ChCl solution. Uptake activity was detected as described previously. CuPh stock solution was prepared by mixing 400 μl of 1.25 M 1,10-phenanthroline in water:ethanol (1:1) and 600 μl of 250 mM CuSO4. The aim of the concentration curve was to explore a concentration through which CuPh could cause partial inhibition and the effects of the different external media could be most clearly shown.

**Restoration of Activity with Dithiothreitol.** HeLa cells expressing CL-EAAT1 and mutants were washed twice with ChCl solution. The corresponding concentration of CuPh was added and incubated at room temperature for 5 minutes. The incubated solution was discarded, and the cells were washed twice with ChCl solution. Next, NaCl solution containing 20 mM DL-dithiothreitol (DTT) was added and the cells were incubated for 5 minutes. The incubated solution was discarded, the cells were washed twice with ChCl solution, and the transport activity of the mutant was detected.

**Inhibition of Transport by Cd**2+. HeLa cells expressing CL-EAAT1 and mutants were washed twice with ChCl solution. Then, 500 mM cadmium chloride in transport solution (150 mM NaCl, 5 mM MKPi (pH7.4), 0.5 mM MgSO4, and 0.3 mM CaCl2) was added and incubated at room temperature for 5 minutes. The incubated solution was discarded, the cells were washed twice with ChCl solution, and the transport activity of the mutant was detected.

**Effects of External Media on Oxidative Inhibition by CuPh or Sulphydryl Reagent.** HeLa cells expressing CL-EAAT1 and mutants were washed with 1 ml ChCl solution. Cells were incubated with different external media with or without the indicated concentrations of CuPh or sulphydryl reagent for 5 minutes at room temperature. The media contained one of the following: NaCl solution, NaCl solution + 1 mM L-glutamate, NaCl solution + 20 μM DL-threo-β-benzoyloxyaspartate (DL-TBOA) (Tocris, Bristol, UK), KCl solution [150 mM KCl, 5 mM KPi, pH 7.4, 0.5 mM MgSO4, and 0.3 mM CaCl2], or ChCl solution. The medium was sequentially removed and cells were washed twice with the ChCl solution. Transport-mediated D-[3H]-aspartate uptake was detected. Each experiment was performed at least three times.

**Statistical Analysis.** Data are presented as the mean ± S.D. of three independent experiments. Data analysis was performed with SPSS 20.0 statistical software (SPSS Inc., Chicago, IL) using one-way analysis of variance with post-hoc comparison via the Dunnet test. Data were considered statistically significant at P < 0.05 or P < 0.01.

**Results**

**Effects of Cysteine Crosslinking on Transport Activity.** We constructed 26 double cysteine transporters between A243C on the TM4b–4c loop and TM7 for this crosslinking study. We identified two double cysteine transporters, A243C/T396C and A243C/A414C (Fig. 2A), exhibiting a decrease in transport activity after exposure to CuPh. The other transporter mutants showed no change in transport activity after exposure to CuPh. The activity of A243C/T396C and A243C/A414C was inhibited by CuPh in a dose-dependent manner (Fig. 2, B and C). Preincubation of HeLa cells expressing the double mutant with 600 μM CuPh resulted in inhibition of transport by more than 35% (Fig. 2, B and C). Very little inhibition was seen with the single mutant, similar to results with CL-EAAT1 (Fig. 2D). Except for A243C, all other mutants exhibited lower transport activity than CL-EAAT1 (Fig. 2E).

**Expression of Cysteine Mutants.** To determine the association between decreased transport activity and membrane expression of the mutant, surface biotinylation was performed. Cell surface expression of mutants was measured using membrane-impermeable biotin labeling and immunoblotting supplemented with densitometric analysis of developed bands (Fig. 3A). The total protein content of A243C/T396C and A243C/A414C showed a slight decrease compared with CL-EAAT1 (Fig. 3B). Cell surface expression of A243C/T396C and A243C/A414C exhibited a pronounced decline as shown in Fig. 3, A and C. The expression of nonbiotinylated proteins of A243C/T396C and A243C/A414C declined compared with CL-EAAT1 (Fig. 3, A and D). Compared with CL-EAAT1, uptake activity normalized to relative cell surface expression of all mutants decreased (Fig. 3E), although the ratio of biotinylated proteins to nonbiotinylated proteins showed no statistically significant decrease (Fig. 3F).

**Effects of Dithiothreitol on Crosslinking in Double Cysteine Transporters.** To determine whether the effect of CuPh treatment on the two double cysteine transporters was reversible, HeLa cells expressing A243C/T396C and A243C/A414C were first incubated with CuPh and then with the reducing agent, DL-dithiothreitol. DTT restored transport...
activity of both paired cysteine transporters. While the transport activities of A243C/T396C and A243C/A414C were inhibited to 45.5% ± 5.1% and 60.6% ± 4.1%, respectively, by the application with 600 μM CuPh, 20 mM DTT restored the transport activities of the double mutants up to 90.7% ± 8.9% and 95.5% ± 7.6%, respectively (Fig. 4, A and B). We also confirmed that DTT had no effect on the activity of CL-EAAT1 (data not shown).

**Inhibition of Transport of Cysteine Mutants by Cadmium.** To determine whether the amino acid sites A243C and T396C or A243C and A414C in the mutant were close in space, we assessed the effects of cadmium. Cadmium, the divalent cation, is known to interact with cysteinyl side chains and it has been shown that the affinity of the interaction is increased dramatically if the Cd^{2+} ion can be coordinated by two cysteines (Glusker, 1991; Pérez-García et al., 1996). Exposure of the single mutant (A243C, T396C, and A414C), double cysteine mutants (A243C/T396C and A243C/A414C), or cells cotransfected with single cysteine mutants (A243C co T396C or A243C co A414C). (A–D) Cells expressing mutants and CL-EAAT1 were treated with CuPh in NaCl solution for 5 minutes at room temperature, and subsequently D-[3H]-aspartate transport was assayed. Data represent percentage of the remaining uptake activity after incubation with CuPh relative to the values obtained in the absence of CuPh and represented as the mean ± S.D. of four different experiments done in triplicate. **P < 0.01 vs. CL-EAAT1 using one-way analysis of variance (ANOVA) (n = 4).** (E) Transport activity of cysteine mutants and CL-EAAT1. Data are given as a percentage of CL-EAAT1 transport activity and are shown as the mean ± S.D. of three experiments. Values that are statistically and significantly different from those of CL-EAAT1 were determined by one-way ANOVA (*P < 0.05; **P < 0.01, n = 3).

**Effect of External Media on Crosslinking in Double Cysteine Transporters.** To investigate the effect of substrate transport and inhibitor binding on disulfide crosslinking of cysteine pairs, HeLa cells expressing A243C/T396C
and A243C/A414C were incubated with CuPh-supplemented external media. Glutamate and potassium increase the proportion of inward-facing conformation, while DL-TBOA increases the proportion of transporters in the outward-facing conformation (Boudker et al., 2007; Shlaifer and Kanner, 2007; Reyes et al., 2009). Addition of glutamate, potassium, or DL-TBOA augmented the disulfide bond formation in the A243C/T396C mutant (Fig. 5A). While addition of glutamate reduces disulfide bond formation in A243C/A414C, potassium and DL-TBOA showed no effect on A243C/A414C (Fig. 5B).
Aqueous Accessibility of Single Cysteine Transporters T396C and A414C. We used membrane-impermeable sulfhydryl reagent [2-(trimethylammonium)ethyl] methanethiosulfonate (MTSET) and membrane-permeable 2-aminoethyl methanethiosulfonate (MTSEA) for aqueous accessibility of individual cysteines. Sulfhydryl reagent can interact with cysteine residue and form a disulfide bond. This reaction can lead to variable degrees of loss of function of the glutamate transporter, depending on the location of the cysteine and the importance of that position to the function of the glutamate transporter. MTSET can interact with cysteine residue from the extracellular side. However, MTSEA can permeate the membrane and interact with cysteine residue from either side of the membrane (Holmgren et al., 1996). Cells expressing CL-EAAT1, T396C, and A414C were preincubated in the presence of MTSET (Fig. 6A). A414C was found to be sensitive to MTSET (Fig. 6A) since its transport activity was inhibited by 0.5 mM MTSET. However, T396C was not impacted by MTSET (Fig. 6A). Different external media do not affect the inhibition of A414C by MTSET (Fig. 6B). To further investigate accessibility of single cysteine T396C and A414C from cytoplasm, cells expressing CL-EAAT1, T396C, and A414C were preincubated in the presence of MTSEA (Fig. 6C). The activity of the T396C and A414C was inhibited by MTSEA in a dose-dependent manner and full inhibition of transport activity of T396C was observed with increased MTSEA concentration to 5.0 mM (Fig. 6C). Protection was observed in the presence of glutamate, potassium, and DL-TBOA by MTSEA in T396C (Fig. 6D). No effect on inhibition of transport activity was observed by MTSEA in A414C with different external media (Fig. 6E).
Discussion

Our previous results suggested that introduction of pairwise cysteine substitutions between the TM2 and TM4 domains caused the glutamate transporter EAAT2 to undergo a complex conformational shift during transport cycle (Rong et al., 2016). However, TM2 is the constituent of the scaffold domain and has been considered to maintain the relative balance of the transporter during the translocation of the substrate (Yernool et al., 2004; Canul-Tec et al., 2017). Thus, we assumed that the TM4 domains might participate in the translocation of the substrate. Furthermore, N-glycosylation sites in the TM4 are also observed in human SLC1 transporters, which suggest that this loop may play a significant part in the post-translational processing of transporters (Canul-Tec et al., 2017). Some amino acid mutations and deletions were made in the TM4b-c loop of the structure of the EAAT1 crystal mutant; therefore, most residues in the TM4b-4c loop could not be modeled (Canul-Tec et al., 2017). Previous studies have postulated that amino acid residues in the TM4b-4c loop present in mammalian EAATs were accessible to the extracellular region (Pines et al., 1992; Grunewald et al., 1998; Seal et al., 2000). Fluorescence resonance energy transfer (FRET) analysis also indicated that the TM4b-4c loop was accessible to the extracellular media (Koch and Larsson, 2005). TM7 is divided at the cell surface by the β-bridge into two helices and constitutes one part of the translocation pore for substrates and cotransported ions (Seal and Amara, 1998). We have previously demonstrated that Ala243 on TM4 forms disulfide crosslinking to HP1 or HP2 (Rong et al., 2014). We also suggested that Ala243 on the TM4b-4c loop was conformationally sensitive and might play a role in the transport pathway during the transport cycle (Zhang et al., 2018). To determine the spatial proximity and functional significance of residues in the glutamate transporter, EAAT1, we created

![Fig. 6. Effect of external media on the inhibition of transport activity by MTSET or MTSEA in T396C and A414C.](image-url)
pairs of cysteine residues in A243 on the TM4b-4c loop and β-bridge region of TM7 or the tip of TM7, and assessed the effect of disulfide crosslinking with CuPh on transport activity. We authenticated two double cysteine transporters, A243C/T396C and A243C/A414C, which exhibit decreased transport activity when exposed to CuPh (Fig. 2, A–D). We observed that increasing concentrations of CuPh (1–600 μM) lead to greater reduction in glutamate transport for both transporters (Fig. 2, B and C). To determine whether there was a decrease in the expression of inactive mutant transporters at the plasma membrane or if the mutations intrinsically affected transport activity, surface biotinylation was performed. The decreased transport activity of A243C/T396C and A243C/A414C can be explained, in part, by the inability of the transporters to traffic into the plasma membrane, as evidenced by their dramatic absence from the biotinylated fraction (Fig. 3, A and C). Uptake activity normalized to relative cell surface expression also shows that all mutants have an intrinsic transport defect (Fig. 3E).

CuPh can lead to the formation of covalent links between cysteines, and the reversibility in the presence of DTT confirms the formation of a disulfide bond. Transport activity was restored with 20 mM DTT in both double cysteine transporters (Fig. 4, A and B). Additionally, transport activity in single mutants was unaffected by incubation with CuPh. Thus, we demonstrated that disulfide bonds formed in A243C/T396C and A243C/A414C were reversible and occurred within single subunits rather than between multiple subunits. A complementary approach to assess the proximity between cysteines in the TM4b-4c loop and TM7 is incubated with cadmium. The transport activity of double mutants was decreased and formed a high-affinity Cd2+ binding site (Fig. 4, C and D). This result was in accordance with the inhibition of CuPh, which further suggested that A243 on the TM4b-4c loop was in close proximity to T396 and A414 on TM7.

To maximize the effect of the change in disulfide crosslinking of cysteine pairs in the double cysteine mutants, cells expressing mutants were exposed to CuPh in the presence of different external media. DL-TBOA and the nontransported and competitive inhibitors are thought to bind similar sites as substrates, either inducing or stabilizing particular conformations. It was expected to increase the proportion of outward-facing transporters (Boudker et al., 2007). On the contrary, binding of L-glutamate might either directly block the access of other reagents to the cysteine side chain or stabilize a particular conformation such that access to the side chain is restricted. It is expected that the proportion of inward-facing transporters will be increased in the presence of glutamate (Reyes et al., 2009). It is also believed that the potassium relocation step is the rate-limiting step during the transport cycle, and hence the proportion of inward-facing transporters is expected to increase when external potassium replaces sodium (Bergles et al., 2002). Transport activity was reduced when glutamate or potassium or DL-TBOA was coincubated with CuPh in A243C/T396C (Fig. 5A). This indicated that disulfide bond formation increased and the transport activity was impaired. It can be observed that during the transport cycle not only outward-facing but also inward-facing transporters cause A243C to come into close proximity to T396C of the β-bridge region in TM7. The β-bridge region in TM7 might undergo significant inward motion relative to TM4 of the scaffold domain in outward- and inward-facing transporters. In the case of the A243C/A414C transporter, transport activity was increased upon coincubation of glutamate with CuPh (Fig. 5B). However, there may be uncertainties since the protective effect in the experiment is only about 10%, even though P < 0.05. Furthermore, A414C, which is on the very tip of TM7, can crosslink with A243C, which is expected to be near the beginning of TM4c. This implies a very large incursion of the transport domain, much deeper than observed in crystal structures of GltPh. Most of the glutamate transporters will form crosslinks between TM4b-4c and TM7 in the outward- or inward-facing transporter phases. This does not rule out the possibility that the TM4b-4c loop may be sufficiently flexible and that crosslinks with TM7 are in rare interludes for a few transporters. Ca-Ca distances from
the crystal of GltPh, between V151 and T308 or A326, which are equivalent to A243 and T396 or A414 of EAAT1, are similar in substrate-binding and outward-facing, but not in inward-facing, structures (8.7, 8.1, and 20.3 Å for V151 to T308; 35.7, 35, and 18.7 Å for V151 to A326) (Fig. 7). Our results are inconsistent with these data. The mechanism and structure of the TM4b-4c loop in the eukaryotic glutamate transporter may differ from that of GltPh, for differences in the quantity of residues. The extra 53 amino acid residues of the TM4b-4c loop in EAAT1 may lead to differences in spatial or configurational proximity during the transport cycle compared with that of GltPh.

The alteration of the inhibitory effect of CuPh in double cysteine transporters may be explained as the change of proximity between the TM4b-4c loop and TM7 or the modification of accessibility of the single cysteine residues. A414C was inhibited by MTSET, but glutamate, potassium, and DL-TBOA protected T396C against MTSEA (Fig. 6, C and D). There are two possibilities: 1) the reduced accessibility of T396C in the inward- or outward-conformational states or 2) the close proximity of T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites. In the presence of sodium, when fully loaded with glutamate or T396C to the substrate or sodium-binding sites.


Address correspondence to: Shaogang Qu, Central Laboratory, Shunde Hospital, Southern Medical University, Foshan, Guangdong 528300, China. E-mail: sgq9528@163.com